Immunoelectrophoretic characterization of plasma fibrinogen derivatives in patients with pathological plasma proteolysis.
D000179:Acrylates; D000362:Agar; D000614:Aminocaproates / Q000627:therapeutic use; D000818:Animals; D001778:Blood Coagulation Disorders / Q000175:diagnosis*; D001780:Blood Coagulation Tests; D004586:Electrophoresis; D005112:Extracorporeal Circulation; D005340:Fibrinogen / Q000032:analysis*; D005341:Fibrinolysin / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D005782:Gels; D006801:Humans; D007106:Immune Sera; D007122:Immunoelectrophoresis; D008103:Liver Cirrhosis / Q000188:drug therapy; D008297:Male; D008970:Molecular Weight; D009539:Nicotinic Acids / Q000494:pharmacology; D010949:Plasma / Q000032:analysis; D011471:Prostatic Neoplasms / Q000188:drug therapy; D011817:Rabbits
D000179:Acrylates; D000614:Aminocaproates; D005343:Fibrinolytic Agents; D005782:Gels; D007106:Immune Sera; D009539:Nicotinic Acids; D005340:Fibrinogen; D000362:Agar; D005341:Fibrinolysin